TITLE

G8 attention to neglected diseases research welcomed

AUTHOR(S)
Silversides, Ann
PUB. DATE
August 2008
SOURCE
CMAJ: Canadian Medical Association Journal;8/12/2008, Vol. 179 Issue 4, p316
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the Drugs for Neglected Diseases Initiative (DNDi), an independent and non-profit pharmaceutical organization faces the challenge of running clinical trials on promising drugs in remote, hard-to-access parts of the world. The Group of Eight (G8) pledged to support research into treatments for neglected diseases of the newly opened North American branch of DNDi based in New York City. The mission of the pharmaceutical organization is to discover and develop new drugs and ensure access to treatments for three tropical diseases which are sleeping sickness, leishmaniasis, and Chagas. The initiative was created because the market-driven drug development system was not researching treatments for patients in the developing world.
ACCESSION #
33461838

 

Related Articles

  • Advancing Drug Innovation for Neglected Diseases--Criteria for Lead Progression. Nwaka, Solomon; Ramirez, Bernadette; Brun, Reto; Maes, Louis; Douglas, Frank; Ridley, Robert // PLoS Clinical Trials;Aug2009, Vol. 6 Issue 8, Special section p1 

    The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery....

  • Southern comfort for world's "neglected" diseases.  // New Scientist;11/7/2009, Vol. 204 Issue 2733, p7 

    The article reports on the efforts launched by newly industrialized countries to develop cheap treatments for tropical diseases that are often neglected by the pharmaceutical industry. Between 1975 and 2004, 1,556 drugs have been approved but only 21 of such approved drugs were for tropical...

  • TAKING ON NEGLECTED DISEASES.  // New Scientist;9/30/2006, Vol. 191 Issue 2571, p6 

    This article presents information about a meeting of scientists, organized in September 2006 in Nairobi, Kenya. They discussed different issues related to tropical diseases. These diseases account for about 12% of global sickness, yet only 1.3% drugs were developed during 1975-2004 for their...

  • The expanding global health agenda: a welcome development. Fauci, Anthony S. // Nature Medicine;Oct2007, Vol. 13 Issue 10, p1169 

    The article offers information that international bodies such as United Nations and Group of Eight organization have taken up the challenge to improve world health conditions. It is stated that the main focused areas for health improvement are the underdeveloped countries that have poor medical...

  • Incorporating a Rapid-Impact Package for Neglected Tropical Diseases with Programs for HIV/AIDS, Tuberculosis, and Malaria. Hotez, Peter J.; Molyneux, David H.; Fenwick, Alan; Ottesen, Eric; Sachs, Sonia Ehrlich; Sachs, Jeffrey D. // PLoS Medicine;May2006, Vol. 3 Issue 5, pe102 

    The article discusses the battle against neglected tropical diseases such as avian influenza and the big three diseases, AIDS/HIV, tuberculosis and malaria. The Group of 8 and the United Nations are increasing their efforts in helping people in developing countries living on less than U.S. $2 a...

  • The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study. Wells, Susan; Diap, Graciela; Kiechel, Jean-RenĂ© // Malaria Journal;2013, Vol. 12 Issue 1, p1 

    Background: The Drugs for Neglected Diseases initiative (DNDi) is a not-for profit organization committed to providing affordable medicines and access to treatments in resource-poor settings. Traditionally drug development has happened "in house" within pharmaceutical companies, with research...

  • Of Pills and Profits: In Defense of Big Pharma. Huber, Peter W. // Commentary;Jul/Aug2006, Vol. 122 Issue 1, p21 

    The article looks at the criticisms against the pharmaceutical industry in the U.S. The industry neglects many essential drugs that treat rare diseases. Pharmaceutical companies claim that research-and-development costs for a new drug can be up to $2 billion. The industry should narrow their...

  • Pharma research for tropical diseases. John, Jacob E. // Current Science (00113891);11/10/2006, Vol. 91 Issue 9, p1127 

    The article presents the author's views on the state of pharmaceutical research for tropical diseases in India. The cost of developing drugs in India is compared with that in Europe and the U.S. The course of action that would enhance the development of drugs in India involves the funding of...

  • The Unaccountable G-8. SACHS, JEFFREY D. // International Economy;Summer2010, Vol. 24 Issue 3, p42 

    The article provides information on the discussions of G-8 summit in Canada. It states that G-8 had not fulfilled its promises to Africa. It further states that G-8 should be dropped and in place of it G-20 should be focussed because it includes developing countries as well. There should be...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics